Premarket · Imaging & AI/SaMD

FDA Cybersecurity Deficiency Response for Imaging AI & SaMD

Resolve FDA cybersecurity deficiency letters fast for imaging AI and SaMD - model lineage, DICOM, cloud tenancy, and PCCP-aligned security responses.

Book a strategy session FDA Deficiency Response

How this applies to Imaging & AI/SaMD

Cybersecurity deficiency letters for imaging AI and SaMD typically cluster around three themes: incomplete SBOM (especially missing OS-layer or model artifacts), insufficient threat modeling of the cloud architecture and tenancy boundaries, and missing security architecture views for the inference and writeback paths. We've closed deficiency letters in this segment that were structured exactly that way. Our 24-hour gap analysis maps each item in your AI letter or hold letter to the specific FDA guidance section it references - current 524B guidance, the AI/ML PCCP draft, and the 2026 final premarket guidance - and identifies whether the gap is a documentation problem, an analysis problem, or an actual product-side gap that needs a design change.

For imaging AI specifically, the most common 'real' (not just documentation) gaps we resolve are: tenant-isolation evidence missing for the cloud inference path, model-update path not security-modeled in the PCCP, DICOM security profiles not analyzed, and SBOM that doesn't include model weights or container OS layers. We rebuild the affected SPDF sections, add the missing threat model coverage, regenerate the SBOM with VEX, and produce a response letter structured for the reviewer who issued the deficiency - changes flagged, justifications cross-referenced to guidance sections, and the package eSTAR-ready. We stay engaged through any second round at no additional cost.

Common findings

Common findings in Imaging & AI/SaMD fda deficiency response

The patterns we actually see in this segment, this service, again and again.

SBOM rejected for missing OS-layer + model components

Common pattern: pip-freeze SBOM accepted at first submission, rejected with 'incomplete' on review. We rebuild as multi-layer CycloneDX with model artifacts.

Tenant isolation not demonstrated

Cloud architecture described, isolation controls not evidenced. Resolved by adding tenant-isolation control test evidence to the SPDF and threat model.

PCCP doesn't address model-update security

PCCP focuses on clinical performance bounds. Reviewer asks how a malicious model update is prevented - we add that branch to the PCCP cyber controls.

DICOM security profile choice not justified

Product uses no DICOM security profile. Response documents the threat-model rationale and compensating controls.

What you get

Standard FDA Deficiency Response deliverables

These are the same deliverables the parent FDA Deficiency Response service ships with - tuned to your imaging & ai/samd architecture.

24-hour gap analysis: We map every item in the deficiency letter against the specific FDA guidance section it references - so the response addresses what reviewers actually want, not what the letter superficially says.
Remediation package: Every artifact identified in the gap analysis is rebuilt or updated - SPDF sections, SBOM, test evidence, or threat model - formatted for the eSTAR template and traceable to the deficiency items.
Reviewer-ready response: The final package is structured for the FDA reviewer who issued the letter - changes are flagged, justified, and cross-referenced so they can close the deficiency without a second round.
Post-submission support: We stay on the engagement until the deficiency is resolved - if FDA responds with a second round, we address it at no additional cost.

Standards